Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
epidemiology
infection
inflammatory bowel disease
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
21
02
2022
received:
05
11
2021
accepted:
22
02
2022
pubmed:
19
3
2022
medline:
15
6
2022
entrez:
18
3
2022
Statut:
ppublish
Résumé
It is unclear how the compounding prevalence of inflammatory bowel disease (IBD) has translated into the causes and rates of hospitalisation, particularly in an era of increased biologic prescribing. We aimed to analyse these trends in a population-based IBD cohort over the last 10 years. The Lothian IBD registry is a complete, validated, prevalent database of IBD patients in NHS Lothian, Scotland. ICD-10 coding of hospital discharge letters from all IBD patient admissions to secondary care between 1 January 2010 and 31 December 2019 was interrogated for admission cause, with linkage to local/national data sets on death and prescribed drugs. Fifty-seven per cent (4673/8211) of all IBD patients were admitted to secondary care for >24 h between 1 January 2010 and 31 December 2019. In patients <40 years, IBD was the commonest reason for admission (38% of admissions), whereas infection was the most common cause in those >60 years (19% of admissions). Three per cent (243/8211) of IBD patients accounted for 50% of the total IBD bed-days over the study period. Age-standardised IBD admission rates fell from 39.4 to 25.5 admissions per 100,000 population between 2010 and 2019, an average annual percentage reduction of 3% (95% CI -4.5% to -2.1%, p < 0.0001). Non-IBD admission rates were unchanged overall (145-137 per 100,000 population) and specifically for serious (hospitalisation) and severe (ITU admission or death) infection over the same period. Despite compounding prevalence and increased biologic use, IBD admission rates are falling. The cause of admission varies with age, with infection the predominant cause in older patients.
Identifiants
pubmed: 35301734
doi: 10.1111/apt.16867
pmc: PMC9314623
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-76Subventions
Organisme : Medical Research Council
ID : MR/S034919/1
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Clin Gastroenterol Hepatol. 2006 May;4(5):621-30
pubmed: 16678077
BMJ Open Gastroenterol. 2018 Mar 20;5(1):e000191
pubmed: 29607052
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
Gastroenterology. 2006 Sep;131(3):719-28
pubmed: 16952541
J Crohns Colitis. 2021 Dec 18;15(12):2011-2021
pubmed: 34089587
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
J Crohns Colitis. 2021 Dec 18;15(12):1991-2000
pubmed: 34019625
Gut. 2019 Nov;68(11):1953-1960
pubmed: 31300515
Gastroenterology. 2019 Apr;156(5):1345-1353.e4
pubmed: 30639677
J Crohns Colitis. 2020 Sep 16;14(9):1241-1247
pubmed: 32840295
Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53
pubmed: 18550004
Aliment Pharmacol Ther. 2022 Jul;56(1):67-76
pubmed: 35301734
Colorectal Dis. 2021 May;23(5):1175-1183
pubmed: 33350054
Gut. 2014 May;63(5):771-5
pubmed: 23744613
Gastroenterology. 2018 Feb;154(3):518-528.e15
pubmed: 29102619
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1736-1743.e4
pubmed: 30616024